NP and PA

Survey highlights quality of life sentiment among patients with AD
September 07, 2020

Only half of patients are satisfied with their atopic dermatitis treatment; yet, only about one-third discuss their quality-of-life concerns with their healthcare provider, a recent survey reveals.

Behavioral economics concepts guide tactics to promote patient engagement, treatment compliance
July 15, 2020

Steven R. Feldman, M.D., Ph.D., describes several tactics based on concepts from behavioral economics that can be implemented in counseling conversations with patients.

Weekly Roundup: June 22-26
June 26, 2020

ICYMI, this week’s edition features a video series on social media use in dermatology, the launch of our new podcast, as well as articles about FDA approvals for acne and cSCC, progress in epidermolysis bullosa, new rosacea management treatment, plus more.

Research gains traction for hidradenitis suppurativa
June 05, 2020

Efforts are underway to identify new therapeutic methods that can offer improved outcomes for patients with hidradenitis suppurativa.

The immunocompromised dermatology patient and COVID-19
May 26, 2020

In light of the ongoing pandemic, Vivian Shi, M.D., discusses potential risks dermatologists will want to keep in mind when evaluating patients currently taking immunomodulator or immunosuppressant drugs.

Addressing the aesthetic needs of millennials
May 15, 2020

Dr. Suneel Chilukuri of Refresh Dermatology located in Houston, Tx., sits down with Dermatology Times to discuss the aesthetic needs of millennial patients and what they've been requesting, such as treatment for 'tech neck' and much more.

Trifarotene cream proves safe, effective for acne vulgaris
May 11, 2020

A recent clinical review proves trifarotene 0.005% cream is an effective and safe treatment for acne vulgaris on the face and neck in patients 9 years and older. Currently, the drug is one of four topical retinoid acne treatments available on the market.

IL-23 antagonist demonstrates favorable long-term safety
May 06, 2020

The interleukin-23 antagonist guselkumab demonstrated greater efficacy compared with adalimumab and secukinumab at week 48 in controlled clinical trials investigating treatment of moderate-to-severe plaque psoriasis.

Mast cells may play key role in rosacea pathogenesis
May 06, 2020

Mast cells appear to play an intricate role in the pathophysiology of rosacea and could serve as potential targets for future therapies, according to recent study findings.